I
Imperagen
Closed-loop AI and robotics platform for digital enzyme evolution
About Imperagen
Imperagen is a Manchester Institute of Biotechnology techbio spin-out building a closed-loop Digital Enzyme Evolution platform that combines quantum-physics simulation, problem-specific AI models and automated robotics to engineer high-performance enzymes for pharmaceuticals, personal care, sustainable chemicals and industrial biotech. Founded by Dr Andrew Almond with Andrew Currin and Timothy Eyes, and led as CEO by Guy Levy-Yurista (joined with the 2026 round), Imperagen reports multi-hundred-fold enzyme productivity gains across few experimental rounds. After a £3.5 million 2022 seed, in May 2026 Imperagen raised a £5 million seed led by PXN Ventures with IQ Capital and Northern Gritstone returning, bringing total funding to about £8.5 million to scale R&D, wet lab and go-to-market. Sources: Tech.eu 21 May 2026; TechCrunch 20 May 2026.
Source: Dealroom company dataAt a glance
- Founded
- 2021
- Headquarters
- Manchester, United Kingdom
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
IQ Capital
Northern Gritstone
PXN Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Imperagen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Imperagen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.